

# Chee Wah Tan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2316393/publications.pdf>

Version: 2024-02-01

40  
papers

4,563  
citations

279487

23  
h-index

264894

42  
g-index

48  
all docs

48  
docs citations

48  
times ranked

9751  
citing authors

#	ARTICLE	IF	CITATIONS
1	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 612.e1-612.e7.	2.8	231
2	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection <i>In Vitro</i> , despite Eliciting a Prolonged Antiviral Response. <i>MBio</i> , 2022, 13, e0343621.	1.8	12
3	Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. <i>EMBO Molecular Medicine</i> , 2022, 14, e15227.	3.3	31
4	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. <i>Lancet Microbe</i> , The, 2022, 3, e81-e82.	3.4	56
5	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. <i>Vaccines</i> , 2022, 10, 639.	2.1	18
6	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 2088-2096.	2.9	23
7	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. <i>Clinical Infectious Diseases</i> , 2021, 73, e2932-e2942.	2.9	143
8	Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. <i>Journal of Medical Virology</i> , 2021, 93, 647-648.	2.5	19
9	Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. <i>Nature Communications</i> , 2021, 12, 972.	5.8	276
10	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108728.	2.9	568
11	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. <i>PLoS ONE</i> , 2021, 16, e0246864.	1.1	20
12	Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice. <i>Vaccine</i> , 2021, 39, 1708-1720.	1.7	7
13	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. <i>Lancet Microbe</i> , The, 2021, 2, e240-e249.	3.4	322
14	Bat virome research: the past, the present and the future. <i>Current Opinion in Virology</i> , 2021, 49, 68-80.	2.6	17
15	SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. <i>Scientific Reports</i> , 2021, 11, 2062.	1.6	58
16	Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection. <i>MBio</i> , 2021, 12, e0234221.	1.8	11
17	Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women. <i>Frontiers in Immunology</i> , 2021, 12, 783975.	2.2	29
18	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. <i>Nature Biotechnology</i> , 2020, 38, 1073-1078.	9.4	1,042

#	ARTICLE	IF	CITATIONS
19	Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. <i>MBio</i> , 2020, 11, .	1.8	245
20	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020, 9, 900-902.	3.0	89
21	Serological differentiation between COVID-19 and SARS infections. <i>Emerging Microbes and Infections</i> , 2020, 9, 1497-1505.	3.0	89
22	Connecting clusters of COVID-19: an epidemiological and serological investigation. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 809-815.	4.6	229
23	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. <i>PLoS Pathogens</i> , 2020, 16, e1009130.	2.1	98
24	An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report. <i>Journal of Biomedical Research</i> , 2020, 34, 470.	0.7	8
25	Immune responses against enterovirus A71 infection: Implications for vaccine success. <i>Reviews in Medical Virology</i> , 2019, 29, e2073.	3.9	18
26	Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. <i>PLoS Pathogens</i> , 2019, 15, e1007863.	2.1	22
27	Serological evidence and experimental infection of cynomolgus macaques with pteropine orthoreovirus reveal monkeys as potential hosts for transmission to humans. <i>Emerging Microbes and Infections</i> , 2019, 8, 787-795.	3.0	8
28	Cell surface $\alpha$ 2,3-linked sialic acid facilitates Zika virus internalization. <i>Emerging Microbes and Infections</i> , 2019, 8, 426-437.	3.0	29
29	Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. <i>Nature Microbiology</i> , 2019, 4, 789-799.	5.9	245
30	Serological evidence of human infection by bat orthoreovirus in Singapore. <i>Journal of Medical Virology</i> , 2019, 91, 707-710.	2.5	18
31	Characterization of a filovirus (MÄnglÄ virus) from Rousettus bats in China. <i>Nature Microbiology</i> , 2019, 4, 390-395.	5.9	116
32	Identification and characterization of neutralization epitopes at VP2 and VP1 of enterovirus A71. <i>Journal of Medical Virology</i> , 2018, 90, 1164-1167.	2.5	3
33	Serological Cross Reactivity between Zika and Dengue Viruses in Experimentally Infected Monkeys. <i>Virologica Sinica</i> , 2018, 33, 378-381.	1.2	4
34	Polysulfonate suramin inhibits Zika virus infection. <i>Antiviral Research</i> , 2017, 143, 186-194.	1.9	67
35	VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. <i>Virology</i> , 2017, 501, 79-87.	1.1	51
36	Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool. <i>PLoS ONE</i> , 2016, 11, e0162771.	1.1	27

#	ARTICLE	IF	CITATIONS
37	Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers. <i>Antiviral Research</i> , 2014, 107, 35-41.	1.9	14
38	Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor. <i>Journal of Virology</i> , 2013, 87, 611-620.	1.5	183
39	Enterovirus 71 receptors: promising drug targets?. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 547-549.	2.0	2
40	Inhibition of Enterovirus 71 (EV-71) Infections by a Novel Antiviral Peptide Derived from EV-71 Capsid Protein VP1. <i>PLoS ONE</i> , 2012, 7, e34589.	1.1	41